Take the bull market of the pharmaceutical industry for two years, this year can be described as difficult, the industry not only in the first quarter compared with last year\\ s revenue and net profit growth year on year downward trend, and industry index continued to fall at the same time, the pharmaceutical industry is also subject to price reduction policy and cost twofold increase in pressure, can be said that fatigue filling.
In contrast, there is no price crisis by medical device industry is Chunfengmanmian, new GMP implementation, which will help the medical device industry to upgrade the overall optimization; peak rural health care institution-building has not ended, the industry will continue the current high degree of prosperity .
Avoid upward pressure on drug prices and costs
\"medical equipment is the pharmaceutical industry since the early 2011\\ s touch of bright colors. Pharmaceutical industry in 2011 from January to April increased revenue growth in the main case, but the total profit growth rate dropped significantly, indicating that the current pharmaceutical industry is facing drug prices and the dual pressures of rising costs, profit margins were squeezed, while the medical devices sub-sector is not subject to price reduction as the impact of policies, continue to maintain a rapid growth of which, a quarterly medical device companies accumulated a total profit of 37.31% of the high-growth, ahead of other sub-sectors, the pharmaceutical industry to become one of the few bright spots. \"controversial for the pharmaceutical industry this year, Xiangcai from another angle to give medical device industry highly.
It is obvious that the reason why the medical device industry can continue to maintain this rapid growth, which they are lucky to avoid upward pressure on drug prices and costs are directly related.
The first half of this year, the pharmaceutical industry is suffering a wave of price cuts, which cut prices of essential drugs is already reflected in the provinces tender, and health insurance directory, anti-infective and circulatory system drugs price reduction policy has also been introduced, follow-up of prices of other categories of drugs policy another floor.
At the same time, traditional Chinese medicine this year, leaving tidal waves of price increases suffered much pharmaceutical companies. Guangzhou Pharmaceutical (15.00,0.07,0.47%) (600 332, closing price of 14.93 yuan) Deputy General Manager Pang Jianhui said the company will expand the GMP base, strengthen cooperation with Chinese herbal origin, centralized purchasing and other means to respond to price increases caused by Chinese herbal medicines impact.
Pharmaceutical industry is in \"dire straits\", but the medical device industry has no trouble. Currently, there are many favorable factors driving the rapid development of medical devices, which is the industry are more concerned about the reason.
Benefit from the aging of the population
In China, the medical device industry is still a new industry, whether production or research and development can not meet all the needs of the market. At present, China\\ s medical device and drug consumption less than 1:5, while in developed countries, this ratio has reached 1:1.
General Manager of Guangdong Nasdaq investment, private equity fund manager Lishi Yu said: \"China\\ s medical market is a rapidly growing market in the past 10 years, compound annual growth rate of 22%, the current market size of 100 billion yuan. Medical device market scale in the proportion of the entire pharmaceutical industry has grown from 8.8% in 2002 to upgrade to the current 12% to 15% in the United States, this ratio is about 35% in China to double this ratio means that there is room. \"
Industry sources say that the future growth of medical equipment, mainly to see the three major driving factors, namely health care system to expand coverage, improve capacity to pay of consumers, and government investment in primary health care system. However, the industry first needs help, or China\\ s aging population trend. At present, China has basically entered the aging early stages of direct expansion of the medical device industry, market demand for capacity.
Lishi Yu pointed out that \"studies have shown that, in 2007, China has gone through demographic change on behalf of the \\ Turning Point\\ , which means the speed of aging will be faster in China over 65 years the proportion of the total population in 1990 5.6% 2010 9.3% 2025 and 2050, this proportion will reach 12.6% and 19.6%, according to Shanghai Research Center on Aging data show that population aging will lead to growth of total health costs rate 1.54%. \"
Demand the release of primary health care sector
The reason why there is a huge medical device development, in addition to the direct stimulation of an aging population, the national policy to support efforts to increase, but also provides a good opportunity for development.
Xiangcai Securities believes that the new medical reform in 2011 as the last year of primary health care institution-building continues, but the focus will be the amount of shift quality construction.
Specific requirements of the Ministry of Health, to the end of 2011, each county (county-level cities) at least a secondary level reached the level of the county hospital, 1 to 3 hospitals to center township standards. Therefore, the county hospitals and township hospitals represented by the rural health institutions will face the full upgrade. Upgrade medical institutions in rural areas mainly in the medical device configuration standards. The estimated period of the new medical reform, hospital equipment each county will invest 5.23 million yuan, compared with 2004 to 2008 period does not exceed $ 1.5 million of medical equipment to enhance significantly the standard configuration.
Xiangcai Securities also pointed out that taking into account the start of 2009 to 2010 there are some medical institutions in rural areas are not completed, estimated in 2011 at least 845 county-level hospitals and township hospitals in 2635 will be built in the construction or condition. Accordingly, the potential of rural medical institutions for medical equipment needs more than $ 6.3 billion in cash is expected before the end of 2012, the medical equipment of high prosperity will continue.
Reporters also learned that the Ministry of Health published in the \"five key health system reform of 2011 the main work\", the support 300 so clearly on the county-level hospitals, 1,000 township health centers and so on more than 13,000 village health room building at the same time, the Ministry of Health also plans, by 2015 all county-level hospitals nationwide have reached the level of secondary level hospitals.
New GMP to accelerate industry consolidation
Policy support at the same time, the formal implementation of the new GMP this year, will also promote industry concentration, positive rapid development of leading enterprises.
New version of the high standards of GMP is mainly reflected in the cleanliness and software management, which is a sterile preparation of pharmaceutical dosage forms in the highest risk, including infusion, freeze-dried powder and water injection, so dedicated a new GMP Sterile Pharmaceutical Appendix, which is the core level of cleanliness, which pharmaceutical companies and sterilization equipment, air purification systems and a higher requirement.
Qianshan medicine machine (30.420, -0.28, -0.91%) (300216, closing price of 30.70 yuan) securities on behalf of the \"Daily Economic News\" reporter, said: \"Medical equipment manufacturing industry is a national health sector was one of more stringent regulatory is high-tech industry, the introduction of new GMP will be eliminated within the industry do not meet the requirements of small and medium enterprises, technology companies will be the core of a larger development space. In addition, the new GMP implementation of a five-year transition period after , and the enterprises still have time to reinvent itself, which also benefit the entire medical device industry, optimization of the overall upgrade. \"
Insiders pointed out that the new GMP for purification, sterile than before a lot of other requirements, if the companies do not have similar equipment, will increase more investment, especially in the higher level of purification of freeze-dried product lines. This requires one, the future of the pharmaceutical equipment industry will be the formation of long-term good.
Focus on individual stocks
Shang Rong Medical (39.99,0.22,0.55%), a leader in operating room
Shang Rong Medical (002,551, closing price of 39.77 yuan) is the largest medical professional engineering service providers, one of the main provider of the operating room as the core of the overall health care professional engineering solutions.
With the rapid development of China\\ s construction of the hospital and operating room gradually spread over the next five years, China\\ s new operating room will remain no less than 20% growth rate. New and existing operating room operating room renovation and update, the next huge market space. Company that in 2011, rebuilt in 2012 is a new outbreak of operating room, the next three years, the industry annual growth rate of not less than 20%.
Shang Rong few medical or industry to undertake the project in the country one of the companies, and has established a nationwide network of more comprehensive marketing services, engineering, the majority of provinces and autonomous regions across the country. The company in the hands of orders for more than 650 million. Expected end of 2011, orders in hand, or more than 10 billion yuan.
TX Irving, said the medical wing will still benefit from the new medical reform, the state continued to increase investment in hospital construction, and the next three years, the transformation of thousands of county hospitals and expansion of high tide.
Xinhua medical (30.50, -0.83, -2.65%), the leading disinfection and sterilization equipment
Xinhua Medical (600,587, closing price of 31.33 yuan) As the first one established medical device companies, strong foundation. The main products include series of infection control, treatment and diagnosis series, pharmaceutical equipment, series, series of environmental protection, medical supplies series. Including medical devices and sterilization equipment as the main product, is the company\\ s main profit growth in the market leading position.
Nadu securities that, from the capital market, the promulgation of the new GMP, pharmaceutical and equipment industry will usher in development opportunities, especially in the new GMP production environment to improve the sterile preparation standards, increase the level of quality assurance of sterile pharmaceuticals , which directly benefit the leading pharmaceutical companies Xinhua medical equipment. In addition, due to the new GMP implementation and primary health care institutions on the hardware level, the company\\ s core business will face new development opportunities.
Dunlop Medical (18.560, -0.04, -0.22%), coronary interventional medical device specialists
Dunlop Medical (300,003, closing price of 18.60 yuan) is mainly engaged in the coronary interventional medical device R & D, production and sales, few can compete with foreign counterparts, domestic companies. The company has formed a PCI (percutaneous coronary intervention) support, supplies, equipment, three business modules.
About 20 million patients with coronary heart disease in China, an annual increase of more than 1 million patients, approximately 95% of patients did not receive effective treatment of myocardial infarction. The next five years, China\\ s PCI cases surgery may be to maintain 30% growth, support continued strong demand is expected to demand $ 10.2 billion. Are three basic domestic stent market monopoly of domestic manufacturers, domestic prices low and quality bracket is its greatest competitive advantage.
CICC expects the next two years, sales of stents to maintain 25% to 30% annual compound growth rate. Dunlop Medical Products launched new restructuring and steady growth of the stent business is the main driving force. In addition, the company will continue to promote the carrier-free stents, bifurcation stents and fully biodegradable stent product substitution process, in order to maintain price stability and promote the sales of stand growth and share gain.
Societe Generale Securities (14.75,0.17,1.17%) also believe that, Dunlop raised funds over the medical use of the advantages listed, through a series of mergers and acquisitions, basically completed the layout in the field of interventional cardiology: cardiac stents, accessories (catheters, guide wires, etc.) , cardiovascular imaging machines, but also signed an agreement with the Chinese side days, co-marketing cardiovascular drugs. The company\\ s strategy is to take full advantage of the marketing channels in the cardiovascular department strengths, to create a wide range of product lines, a comprehensive high-end medical device companies.